Endoscopic Retrograde Market Size, Share and Trends Forecast 2025-2033

Market Overview:

The Endoscopic Retrograde Cholangiopancreatography Market is experiencing significant expansion, driven by Growing Prevalence of Gastrointestinal Disorders, Rising Geriatric Population and Cancer Incidence and Increasing Preference for Minimally Invasive Procedures. According to IMARC Group's latest research publication, "Endoscopic Retrograde Cholangiopancreatography Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025–2033", The global endoscopic retrograde cholangiopancreatography market size reached USD 1.7 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 2.8 Billion by 2033, exhibiting a growth rate (CAGR) of 5.58% during 2025-2033.

This detailed analysis primarily encompasses industry size, business trends, market share, key growth factors, and regional forecasts. The report offers a comprehensive overview and integrates research findings, market assessments, and data from different sources. It also includes pivotal market dynamics like drivers and challenges, while also highlighting growth opportunities, financial insights, technological improvements, emerging trends, and innovations. Besides this, the report provides regional market evaluation, along with a competitive landscape analysis.

Download a sample PDF of this report: https://www.imarcgroup.com/endoscopic-retrograde-cholangiopancreatography-market/requestsample

Our Report Includes:

• Market Dynamics
• Market Trends and Outlook
• Competitive Analysis
• Industry Segmentation
• Strategic Recommendations

Growth Factors in the Endoscopic Retrograde Cholangiopancreatography Industry:

• Growing Prevalence of Gastrointestinal Disorders

In 2025, the global burden of gastrointestinal (GI) and biliary diseases has surged, with a significant rise in choledocholithiasis (bile duct stones) and pancreatic cancers. Changing dietary patterns and rising obesity rates have led to a 15% increase in gallstone-related complications over the last three years. ERCP has become the "gold standard" for managing these complex cases, as it provides a unique dual-purpose platform for both high-resolution diagnosis and immediate therapeutic intervention. The increasing incidence of chronic pancreatitis and malignant biliary strictures is compelling healthcare providers to adopt next-generation ERCP tools that can navigate increasingly difficult anatomical obstructions with higher success rates.

• Rising Geriatric Population and Cancer Incidence

The 2025 market is heavily influenced by "Silver Tsunami" demographics, as the population aged 65 and over is most susceptible to obstructive jaundice and biliary malignancies. In regions like North America and Asia-Pacific, geriatric patients account for nearly 60% of all ERCP procedures. This demographic shift has intensified the demand for specialized, low-trauma devices such as mini-sphincterotomes and flexible stents that accommodate the fragile physiology of older adults. Furthermore, the expansion of oncology-focused diagnostic centers is driving the procurement of advanced endotherapy devices to manage cancer-related ductal obstructions, ensuring palliative care is both effective and minimally invasive.

• Increasing Preference for Minimally Invasive Procedures

A defining shift in 2025 is the migration of ERCP procedures from traditional inpatient surgery suites to Ambulatory Surgical Centers (ASCs). Patients and insurers are increasingly favoring minimally invasive ERCP over open biliary surgery due to its ability to reduce hospital stays by an average of 3.5 days. The refinement of Sphincterotomy and Stenting techniques has turned what was once a high-risk operation into a streamlined, high-throughput procedure. Governments worldwide are supporting this trend by increasing reimbursement rates for minimally invasive interventions, viewing them as a cost-effective solution to manage the growing volume of GI patients while minimizing the post-procedural pain and recovery times associated with traditional surgical approaches.

Key Trends in the Endoscopic Retrograde Cholangiopancreatography Market

• Integration of Artificial Intelligence and Real-Time Decision Support

In late 2025, the industry has embraced AI-assisted ERCP, utilizing computer-assisted detection (CADe) to improve "selective cannulation" success rates. AI algorithms now provide real-time guidance to endoscopists, identifying the optimal entry point for the Major Duodenal Papilla and predicting the difficulty of stone extraction based on anatomical mapping. These "Smart Endoscopy" platforms are also being used to predict the risk of Post-ERCP Pancreatitis (PEP) by analyzing patient biomarkers in real-time during the procedure. This integration of AI is effectively shortening procedural times and reducing the learning curve for junior endoscopists, leading to more standardized and safer clinical outcomes across global healthcare systems.

• Shift Toward Single-Use (Disposable) Duodenoscopes

A major 2025 market trend is the rapid adoption of single-use duodenoscopes, such as the Ambu aScope Duodeno 2, to eliminate the risk of cross-contamination and Healthcare-Associated Infections (HAIs). Historically, the complex elevators and channels of reusable scopes were notoriously difficult to sterilize; however, new regulatory mandates and a 2025 focus on "Infection-Free Surgery" have propelled the single-use segment to a projected 28.4% CAGR. Hospitals are increasingly opting for these disposable alternatives to avoid the high costs of reprocessing, litigation exposure from outbreaks, and the need for expensive high-level disinfection (HLD) infrastructure, making "one-and-done" scopes the new standard for high-risk biliary interventions.

• Expansion of Digital Single-Operator Cholangioscopy (DSOC)

The 2025 ERCP market is witnessing the widespread use of "SpyGlass" style digital cholangioscopy, which allows for direct visualization of the bile ducts. This trend, known as "Doctor-in-the-Duct" technology, enables endoscopists to perform laser or electrohydraulic lithotripsy under direct vision, significantly improving the success rate for "giant" or impacted stones that were previously untreatable via standard ERCP. The integration of high-definition (HD) visualization and 3D reconstruction into these sub-scopes is allowing for more accurate targeted biopsies of indeterminate strictures, transforming ERCP from a blind fluoroscopic procedure into a high-precision, visually guided surgery that drastically reduces the need for repeat interventions.

Our comprehensive endoscopic retrograde cholangiopancreatography market outlook reflects both short-term tactical and long-term strategic planning. This analysis is essential for stakeholders aiming to navigate the complexities of the endoscopic retrograde cholangiopancreatography market and capitalize on emerging opportunities.

Leading Companies Operating in the Global Endoscopic Retrograde Cholangiopancreatography Industry:

• Boston Scientific Corporation
• CONMED Corporation
• Cook Group Incorporated
• Fujifilm Holdings Corporation
• Hobbs Medical Inc.
• Johnson & Johnson
• Medi-Globe GmbH
• Medtronic plc
• Olympus Corporation
• Shaili Endoscopy
• Steris Corporation
• Telemed Systems Inc.

Endoscopic Retrograde Cholangiopancreatography Market Report Segmentation:

Breakup by Product:

• Endoscope
• Endotherapy Devices
• Sphincterotomes
• Lithotripter
• Stents
• Others
• Visualization Systems
• Energy Devices
• Others

Endotherapy devices hold the majority of the total market share as they are essential for performing therapeutic interventions during ERCP procedures including stone removal, stent placement, and sphincterotomy.

Breakup by Procedure:

• Biliary Sphincterotomy
• Biliary Stenting
• Biliary Dilatation
• Pancreatic Sphincterotomy
• Pancreatic Duct Stenting
• Pancreatic Duct Dilatation

Biliary sphincterotomy currently exhibits a clear dominance in the market as it is one of the most commonly performed ERCP procedures for treating bile duct stones and strictures.

Breakup by End User:

• Hospitals and Clinics
• Ambulatory Surgery Centers
• Others

Hospitals and clinics account for the largest market share due to availability of specialized gastroenterology departments, advanced equipment, and trained personnel for performing complex ERCP procedures.

Breakup by Region:

• North America (United States, Canada)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America currently dominates the global market due to high prevalence of pancreaticobiliary diseases, advanced healthcare infrastructure, and strong adoption of minimally invasive procedures.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1–201971–6302